# reload+after+2024-01-22 23:43:17.079123
address1§6310 Town Square
address2§Suite 400
city§Alpharetta
state§GA
zip§30005
country§United States
phone§678 990 5740
fax§678 990 5744
website§https://alimerasciences.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
fullTimeEmployees§150
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Richard S. Eiswirth Jr.', 'age': 55, 'title': 'CEO & Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 597869, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David R. Holland', 'age': 59, 'title': 'Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 413500, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Philip  Ashman Ph.D.', 'age': 58, 'title': 'President of International Operations', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 389858, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Todd Michael Wood', 'age': 54, 'title': 'President', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jason  Werner', 'title': 'Chief Operating Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Christopher S. Visick', 'title': 'VP, General Counsel & Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David  Dyer M.D.', 'title': 'Chief Retina Specialist', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.316
priceToSalesTrailing12Months§2.977662
currency§USD
dateShortInterest§1702598400
forwardEps§0.07
exchange§NGM
quoteType§EQUITY
shortName§Alimera Sciences, Inc.
longName§Alimera Sciences, Inc.
firstTradeDateEpochUtc§1572877800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§43b46644-06cf-3ac0-9514-3b668c1cfa9e
gmtOffSetMilliseconds§-18000000
recommendationMean§2.0
recommendationKey§buy
quickRatio§2.383
grossMargins§0.86366
ebitdaMargins§0.02375
trailingPegRatio§None
